Thank you, operator, and good afternoon, everyone. Our performance in the second quarter was in line with our expectations across revenue, earnings, and it was a bit stronger when it comes to cash flow. We saw strong momentum in our lab equipment and clinical trials business, which helped offset the tough comparison to last year's Q2, when we benefited from several large clean room orders.
While the macroeconomic environment remains uncertain with rising geopolitical tensions and new tariff developments, the market we operate in is holding up relatively well. That said, we are seeing some softness in large CapEx related sales cycles.
We are also experiencing a headwind from the recent strengthening of the SEK, which has impacted our top line and earnings through translation effects.
Looking ahead, our focus remains clear: to continue pushing our acquisition strategy and to deliver sustainable value creation for our shareholders.
With that, let's take a closer look at our Q2 numbers. Our net sales came in at 396 million SEK, which resulted in a year-over-year growth of 4%. Adjusted for FX and excluding FX, EBITDA came in at 61 million SEK, in line with last year's 62, which takes us to a margin of 16%, slightly stronger than last year's 15. Looking at the cash flow from operations, it came in strong at 70 million compared to -19 last year.
During June, we finalized our new financing structure. We have now added proper bank financing combined with bond financing at better terms.
If we apply the new financing structure for this quarter, our proforma net profit will be more than double what is reported.
The proforma figure will be 2023 million SEK, and when compared to the reported 10.8 million, net leverage came in at three times. Taking a closer look at our new financing structure.
Sure, gross debt was reduced by approximately 480 million SEK. Our old SEK and US bonds were partly refinanced with a new SEK bond of 800 million, with a margin of 350 basis points over Stibor, and a new bank facility with a total of 450 million SEK. With a term loan of 15 million USD and an RCF of 300 million SEK. All in all, we have reduced our annual financing costs by approximately 56 million SEK. Two-thirds comes from lower gross debt, and one-third from better terms.
Uh, meaning lower interest margins. The capitalized transaction costs going forward will be about 6 million SEK a year, which is 15 million SEK less than the previous structure. This will only affect the net profit. I mean, no cash flow effect. Coming into the commercial and operational highlights of Q2, we observed stable business momentum in both healthcare and lab sectors during the quarter.
We continue to focus on efficiency initiatives to ensure that we are maximizing our potential to create shareholder value.
Managing working capital is one of our top priorities.
During the quarter, we saw cash flow increase compared to the same quarter last year.
Approximately 42% of our sales in the quarter came from Europe.
And, uh. Second largest market in North America.
And the third is South America.
Looking at our sales by product category, the top three for the year are laboratory equipment.
Uh, 41%, followed by medical consumables at 33%, and medical equipment at 21%. High activity in laboratory equipment and also in clinical trials in the US.
On the topic of tariffs, the direct impact at, I mean, level one, referring to products manufactured outside the US and imported for sales into the US, is relatively limited. We have stated before, and it's the same at this stage. It's 30 to 40 million SEK. Most of our US-based companies both manufacture and sell their products domestically within the US market.
That said, we do rely on certain components sourced internationally for our US production. The positive aspect is that our products are essential in nature, designed to extend, improve, or even save lives, which provides a certain degree of resilience regardless of broader trade dynamics or geographical tensions.
Splitting ADDvise Group into healthcare and lab segments and focusing on healthcare.
Our sales came in at 235 million for the quarter, showing an organic growth of 1% FX adjusted and -8% non-adjusted. Looking at the first six months, we saw an organic growth of 1% and 6% FX adjusted. The lab segment reported sales of 161 million for the quarter.
Organic sales came in at 3% and 8% FX adjusted. Looking at profit margins, healthcare came in at a 15% EBITDA margin and lab came in at 21%. Lab delivered a strong margin.
And I would say healthcare came in at a stable level.
Looking at net sales by geography for the healthcare segment, North America continued to be the key market, with roughly 51% of sales.
And we don't see any big changes going forward. Having said that, Europe has shown good development in the lab segment.
Europe is the largest market, followed by the US.
We remain focused on profitable growth, stable returns, and maintaining a well-balanced debt level, all underpinned by the execution of our acquisition strategy. A strong emphasis is placed on EBITDA growth and return on capital employed as our key financial performance indicators.
EBITDA growth will be driven by a combination of organic expansions and strategic acquisitions.
Our long-term target is to double EBITDA every five years.
A dividend remains part of our long-term financial framework, but distribution will be considered once all other long-term financial goals are at satisfactory levels.
Goals are at satisfactory levels.
We are committed to maintaining a maximum net debt level to EBITDA ratio of three times. While a dividend remains a part, uh.
I mean, the dividend will come into play when all the others of our long-term financial goals are met at a sustainable and appropriate level.
I'm now handing over to Johan to take you through the group's financial performance. Thank you, Staffan, and good afternoon, everyone. I'm happy to be here today and take you through the numbers for the second quarter of 2025.